Mankind Pharma shares jump nearly 8% after the company reports a second-quarter year-on-year rise in profit and revenue. The September-quarter PAT rises about 38% to ₹716 crore, while revenue from operations increases roughly 17% to around ₹4,338 crore, prompting the stock move on the NSE.
Across outlets, the results are attributed to growth in both domestic and international business. Domestic revenue (excluding consumer healthcare) grows about 14.8% year-on-year to ₹3,657 crore, supported by faster growth in certain therapy areas such as cardiac and anti-diabetes products, while exports rise about 32.7% to ₹681 crore. Profitability improves as EBITDA reaches about ₹1,175 crore and margins widen year-on-year.
Different angles focus on what investors should watch next. NDTV highlights consumer healthcare as a “monitorable” area, while separate NDTV items cite brokerages’ views, including Jefferies and Kotak retaining “Buy” but adjusting target prices, and Systematix keeping a “Hold” rating. The Economic Times also emphasizes strategic expansion plans, including an acquisition linked to next-generation CAR-T therapies.
